
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
These aren't happy times for the pharmaceutical industry. Day by day, bad news accumulates, and even the Pharmaceutical Research and Manufacturers Association (PhRMA), the industry's trade organization, acknowledges that something has to give:






